Department of Chemical Physiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
J Immunol. 2011 Feb 1;186(3):1554-63. doi: 10.4049/jimmunol.1003005. Epub 2010 Dec 22.
CD22 is a member of the sialic acid-binding Ig-like lectin (Siglec) family that is known to be a regulator of B cell signaling. Its B cell-specific expression makes it an attractive target for immunotoxin-mediated B cell depletion therapy for the treatment of B cell lymphomas and autoimmune diseases. Although CD22 is well documented to be an endocytic receptor, it is believed that after internalization, it is targeted for degradation. We show in this study that CD22 is instead constitutively recycled to the cell surface. We also find that glycan ligand-based cargo is released from CD22 and accumulates intracellularly as CD22 recycles between the cell surface and endosomal compartments. In contrast, Abs to CD22 do not accumulate but remain bound to CD22 and recycle to the cell surface. The results have implications for development of agents that target CD22 as an endocytic receptor for delivery of cytotoxic cargo to B cells.
CD22 是唾液酸结合免疫球蛋白样凝集素 (Siglec) 家族的成员,已知是 B 细胞信号转导的调节剂。其 B 细胞特异性表达使其成为免疫毒素介导的 B 细胞耗竭治疗 B 细胞淋巴瘤和自身免疫性疾病的有吸引力的靶标。尽管 CD22 被很好地证明是一种内吞受体,但据信它在被内化后被靶向降解。在这项研究中,我们表明 CD22 实际上是不断循环回到细胞表面的。我们还发现,糖基配体基货物从 CD22 释放出来,并在 CD22 在细胞表面和内体隔室之间循环时在细胞内积累。相比之下,针对 CD22 的 Abs 不会积累,而是保持与 CD22 结合并循环回到细胞表面。这些结果对于开发以 CD22 为内吞受体的药物具有重要意义,这些药物可将细胞毒性货物递送至 B 细胞。